![Thomas Meier](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 1 M $ al 31/05/2026
Thomas Meier was the founder of MyoContract AG, founded in 2000, where the title held was Chief Executive Officer from 2000 to 2004.
Dr. Meier is the founder of Santhera Pharmaceuticals Holding AG, founded in 2004, holding the title of Chairman since 2022.
Dr. Meier is the founder of Seal Therapeutics AG, founded in 2021, holding the title of Chairman since 2021.
Current jobs include Executive Chairman at Novaremed AG since 2024, Director at Visgenx, Inc. since 2022, and Managing Partner at Viopas Venture Consulting GmbH.
Former jobs include Chairman at PharmaBiome AG from 2020 to 2021 and Director at Onconetix, Inc. from 2024 to 2026.
Education includes a doctorate conferred in 1992 and graduate studies at the University of Basel.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/12/2024 | 48.878 ( 0,33 % ) | 1 M $ | 31/05/2026 | |
| 13/03/2026 | 13 ( 0 % ) | 16 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Fundador | 07/09/2004 |
Novaremed AG
 Novaremed AG Pharmaceuticals: MajorHealth Technology Develops safer and more efficacious drugs for chronic and life-threatening diseases | Presidente | 01/01/2024 |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting invests in companies located in Europe, primarily in Switzerland, Austria, and Germany. The firm focused on healthcare sectors includes digital health & medtech, pharma and biotech. It provides financing for pre-seed, early and late-stage capital requirements. | Corporate Officer/Principal | - |
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Develops therapeutics to protect against the loss of sight from retinal disorders | Director/Miembro de la Junta | 01/01/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
| ONCONETIX, INC. | Director/Miembro de la Junta | 20/04/2026 |
PharmaBiome AG
 PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services Develop novel platform technologies to formulate microbiota transplant products | Presidente | 01/01/2021 |
MyoContract AG
 MyoContract AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for muscle disorders | Director Ejecutivo | 01/01/2004 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 8 |
|---|---|
MyoContract AG
MyoContract AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for muscle disorders | Health Technology |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
University of Basel
 University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Develops safer and more efficacious drugs for chronic and life-threatening diseases | Health Technology |
PharmaBiome AG
PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services Develop novel platform technologies to formulate microbiota transplant products | Commercial Services |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting invests in companies located in Europe, primarily in Switzerland, Austria, and Germany. The firm focused on healthcare sectors includes digital health & medtech, pharma and biotech. It provides financing for pre-seed, early and late-stage capital requirements. | Finance |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Develops therapeutics to protect against the loss of sight from retinal disorders | Health Technology |
Onconetix, Inc.
 Onconetix, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology drugs and diagnostic test for cancers | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
MarketScreener is also available in this country: United States.
Switch edition
Elige MarketScreener 
